EXEL

Exelixis, Inc. develops and commercializes cancer therapies, focusing on small molecules and biotherapeutics. The company engages in drug discovery and development, with a pipeline that includes treatments for various cancer types. Exelixis operates through internal programs and strategic partnerships, advancing multiple clinical trials aimed at improving patient outcomes in oncology.